Key facts
- NEUROMARK’s last known valuation is $28.8M (May 2020).
- It has raised $147.3M; the latest was Later Stage VC ($74.0M) in Feb 2026.
- Notable investors include Enterprise Ireland, MedTech Innovator, Sofinnova Partners, Claret Capital Partners, Atlantic Bridge Capital — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for NEUROMARK
- ·The full record, as it builds
Funding rounds
No funding rounds for NEUROMARK are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NEUROMARK
Developer of a non-surgical intervention device designed to treat chronic rhinitis safely. The company specializes in minimally invasive hand-held radio-frequency devices that are introduced through the nostrils into the nasal cavity under direct endoscopic visualization where it deploys a microelectrode array that delivers targeted energy to interrupt the autonomic function within the mucosal structures of nasal cavities which will reverse the inflammatory cascade, enabling surgeons to treat patients in an office setting, removing the complications and costs associated with most surgical procedures.
- Sector
- Healthcare
- HQ
- Galway, Ireland
- Founded
- 2014
- Employees
- 70
- Website
- neuromark.com/
- Ownership
- Privately Held (backing)
NEUROMARK doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NEUROMARK shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NEUROMARK in its N-PORT filings yet. We sweep new filings monthly.